Novo Nordisk Files for Regulatory Approval Of Long-Acting Factor IX in EU for Treatment of Haemophilia B
January 07, 2016 at 05:58 AM EST
Novo Nordisk (NYSE: NVO) today announced the submission to the European Medicines Agency of the Marketing Authorisation Application for ...
